Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lipid Screening in Children with NAFLD

J Pediatr; ePub 2018 Apr 13; Harlow, et al

More than 50% of children with nonalcoholic fatty liver disease (NAFLD) met intervention thresholds for dyslipidemia, warranting lipid screening in this population group. This according to a multicenter, longitudinal cohort study that included 585 children (mean age 12.8 years) with NAFLD. Fasting lipid profiles were obtained at diagnosis. After 1 year, lipid profiles were repeated and interpreted according to National Heart, Ling, and Blood Institute Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction. Main outcomes were meeting criteria for clinically actionable dyslipidemia at baseline, and either achieving lipid goal at follow-up or meeting criteria for ongoing intervention. Researchers found:

  • The prevalence of children warranting intervention for low-density lipoprotein cholesterol (LDL-C) at baseline was 14%.
  • After 1 year of recommended dietary changes, 51% achieved goal LDL-C, 27% qualified for enhanced dietary and lifestyle modifications, and 22% met criteria for pharmacologic intervention.
  • Elevated triglycerides were more prevalent, with 51% meeting criteria for intervention.

Citation:

Harlow KE, Africa JA, Wells A, et al. Clinically actionable hypercholesterolemia and hypertriglyceridemia in children with nonalcoholic fatty liver disease. [Published online ahead of print April 13, 2018]. J Pediatr. doi:10.1016/j.jpeds.2018.02.038.

This Week's Must Reads

PAD tied to higher prevalence of LV diastolic dysfunction, Yanaka K et al. J Cardiol. 2019 Feb 18. doi: 10.1016/j.jjcc.2019.01.011

Diabetic kidney disease, retinopathy associated with PAD in patients with foot ulcers, Megallaa MH et al. Diabetes Metab Syndr. 2019 Mar-Apr;13(2):1287-92.

LDL-C & CV Outcomes in Hypertensive Patients, Intl J Cardiol; ePub 2019 Jan 15; Nguyen, et al

High Rates of PCSK9 Inhibitor Access & Initiation, J Clin Lipidol; ePub 2019 Jan 14; Reynolds, et al

Must Reads in Hypercholesterolemia

LDL-C & CV Outcomes in Hypertensive Patients, Intl J Cardiol; ePub 2019 Jan 15; Nguyen, et al

High Rates of PCSK9 Inhibitor Access & Initiation, J Clin Lipidol; ePub 2019 Jan 14; Reynolds, et al

LDL-C Levels and the Risk of Sepsis, JAMA Netw Open; ePub 2019 Jan 18; Feng, et al

Statins for CV Prevention in Elderly Patients, Am J Med; ePub 2019 Jan 18; Bezin, et al

Hypercholesterolemia & Statin Exposure in Cirrhosis, Gastroenterology; ePub 2019 Jan 18; Kaplan, et al